Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of GenVec and has worked at Stifel Nicolaus…

Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…

Cellectar Biosciences announced today the Japanese Patent Office has granted a composition of matter patent for its optical imaging phospholipid drug conjugates (PDCs), CLR 1501 and CLR 1502. “This patent…

Cellectar Biosciences and the Wisconsin Alumni Research Foundation announced it new license agreement for intellectual property rights covering the method of use for the company’s compound, CLR 131, in multiple…

The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as…

Cellectar Biosciences announced recently a clinical benefit rate of 80 percent from its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. “The efficacy…

Cellectar Biosciences today announced the effective price of $1.50 per share of common stock of an underwritten public offering to raise approximately $8 million. According to a release, Cellectar will use…

Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today. According to a release,…

Cellectar Biosciences announced today it is the recipient of the second phase of a National Cancer Institute Fast-Track SBIR contract worth $2 million. According to a release, the money will be used to…

The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers CLR 1603, a phospholipid ether-paclitaxel conjugate, the company announced recently. “This first issued patent under our CLR CTX…